Strong evidence in epilepsy, thin evidence in psychiatry
STUDY: Guo D et al, eClinicalMedicine 2026
STUDY TYPE: Systematic review and meta-analysis
FUNDING: STI2030-Major Projects; National Natural Science Foundation of China
Background
Patients with treatment-resistant illness often ask about medical cannabis. THC acts on cannabinoid receptors and is the compound responsible for the harms of cannabis: addiction, psychosis, and anxiety. Nabilone is a synthetic, medicinal form of THC. CBD lacks those harms and is FDA-approved for rare childhood seizures. It works through serotonin receptors and is neuroprotective. This analysis asks if either help when standard treatments fail in psychiatry and neurology.
The Study
- 127 studies of cannabinoids in treatment-resistant psychiatric and neurologic disorders.
- 32 studies (3,645 patients) had enough data for meta-analysis; only 10 (338 patients) were psychiatric.
- Products ranged from prescription CBD and nabilone to plant extracts.
- No eligible studies existed for treatment-resistant depression or for alcohol or opioid use disorders.
Results
The best evidence came from neurology: add-on CBD reduced seizures in rare syndromes such as Dravet and Lennox-Gastaut (high certainty). Cannabinoids also eased refractory pain and multiple sclerosis spasticity.
Psychiatric findings were small and mostly uncontrolled:
- Nabilone eased PTSD nightmares in a 10-person randomized crossover trial.
- Nabiximols (a cannabis-based oral spray that contains THC and CBD) reduced illicit cannabis use in a 128-person randomized trial (35 vs 53 days over 12 weeks).
- Add-on CBD lowered OCD scores (Y-BOCS 28 to 14) in a 19-person open-label study.
- CBD failed to help anxiety when added to exposure therapy and didn’t improve cognition in schizophrenia.
Certainty was low or very low for every psychiatric finding.
Cannabinoids about doubled the odds of side effects in epilepsy and multiple sclerosis, and epilepsy patients were five times as likely to quit over them. Sleepiness, diarrhea, and elevated liver enzymes were common with CBD.
If we extended the search to non-treatment resistant trials, we’d see more clear evidence for CBD in anxiety and insomnia, and possible benefits for CBD in cannabis dependence, anorexia, and psychotic disorders. We’d also find support for dronabinol, a synthetic THC, in a large trial of PTSD.
Practice Implications
- The evidence doesn’t support medical cannabis for treatment-resistant psychiatric illness, but may have a role in anxiety and PTSD.
- CBD is a reasonable harm-reduction approach that may help people reduce cannabis, but the oral is safer than the vape. Learn how to use it.
—Chris Aiken, MD
Director, Psych Partners
Editor in Chief, Carlat Psychiatry Report







